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Abstract—T helper 1 (Th1) type cytokines and chemokines are bioactive mediators in inflammation
underling several diseases and co-morbid conditions, such as cardiovascular and metabolic disorders.
Th1 chemokine CXCL10 participates in heart damage initiation/progression; cardioprotection has been
recently associated with sildenafil, a type 5 phosphodiesterase inhibitor. We aimed to evaluate the effect
of sildenafil on CXCL10 in inflammatory conditions associated with diabetic cardiomyopathy. We
analyzed: CXCL10 gene and protein in human cardiac, endothelial, and immune cells challenged by
pro-inflammatory stimuli with and without sildenafil; serum CXCL10 in diabetic subjects at cardiomy-
opathy onset, before and after 3 months of treatment with sildenafil vs. placebo. Sildenafil significantly
decreased CXCL10 protein secretion (IC50 = 2.6 × 10
−7) and gene expression in human cardiomyocytes
and significantly decreased circulating CXCL10 in subjects with chemokine basal level ≥ 930 pg/ml, the
cut-off value as assessed by ROC analysis. In conclusion, sildenafil could be a pharmacologic tool to
control CXCL10-associated inflammation in diabetic cardiomyopathy.
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INTRODUCTION
Nowadays, there is growing evidence on a tight associa-
tion between cardiac dysfunction and T helper (Th)1-driven
inflammation [1–3], with the specific involvement of some
cytokines and chemokines, such as tumor necrosis factor
(TNF)α, monocyte chemoattractant protein (MCP)-1 or
CCL2, macrophage inflammatory protein (MIP)1-β or CCL4,
interferon (IFN)-γ-inducible protein-10, IP-10 or CXCL10, in-
terleukin (IL)-8 or CXCL8, IL-1β, IL-6, IL-12, IL-23 [2, 4–11].
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In particular, the chemokine CXCL10 has been
shown to play a pivotal role in early Th1-driven processes
underlying heart damage initiation and progression, i.e.,
during cardiac transplantation, myocarditis, and cardiopul-
monary bypass [12–17]. The level of pretransplant serum
CXCL10 is a predictive biomarker of cardiac damage and
acute organ rejection in heart transplant recipients [12];
furthermore, CXCL10 can be induced and released by
human cardiac cells under inflammatory challenge and
likely contributes to establish and maintain a self-
inflammatory loop between blood and local tissues [12–
16]. This small chemokine is, indeed, one of the major
trigger of activation and polarization of Th1 inflammatory
response both at systemic and tissue level [12, 13, 18–20].
It is quite a recent acquisition that some Th1-driven
processes can be counteracted by the inhibitors of phos-
phodiesterase type 5 (PDE5i) [21]. This class of drugs,
which includes sildenafil, vardenafil, tadalafil, and
avanafil, is widely used as on-demand treatment for erectile
dysfunction (ED) because of the significant vasodilatory
effect achieved through PDE5 inhibition and cyclic gua-
nosine monophosphate (cGMP) stabilization in vascular
beds [22–27]. In view of those vasoactive effects, PDE5
inhibition has been hypothesized as a therapeutic approach
for a number of cardiovascular disturbances as well. Sil-
denafil, in particular, has been shown to exert
cardioprotective effects after ischemia/reperfusion injuries,
reduce infarct size or ventricular arrhythmias [24, 28, 29],
ameliorate heart failure (HF) patients with reduced ejection
fraction (EF), and improve cardiac functional capacity and
geometry in subjects with diabetic cardiomyopathy [30,
31]. Interestingly, studies on effectiveness show that sil-
denafil retains better cardiovascular profile vs. the other
PDE5i [32]. Thus, sildenafil seems a good candidate to be
a therapeutic tool in cardiovascular medicine [25].
It is well-known that vascular bed is the “standard”
target of PDE5i [33, 34].
The purpose of this study is to verify whether sildenafil
could target CXCL10 in human cardiomyocytes challenged
by Th1-type-inflammatory stimuli; IL-6 and IL-8, both in-
volved in inflammation and cell damage in cardiac disease
[35, 36], have been also investigated. Methylprednisolone
(MeP), cyclosporine (CsA), andmycophenolate (MPA)were
used for comparison.We also analyzed the effect of sildenafil
onto CXCL10 in human endothelial and different subtypes
of immune cells (human PBMC, monocytes, macrophages)
in the same experimental conditions. Furthermore, we aimed
to investigate circulating level of CXCL10 in subjects with
diabetic cardiomyopathy, a Th1-driven comorbid condition,
before and after 3 months sildenafil intake vs. placebo.
MATERIALS AND METHODS
Chemicals
Dulbecco modified eagle medium (DMEM)/Ham’s
F-12 medium (1:1) with and without phenol red, RPMI
1640, phosphate buffered saline Ca2+/Mg2+-free (PBS),
bovine serum albumin (BSA) fraction V, antibiotics,
NaOH, EDTA-trypsin solution, Bradford reagent, meth-
ylprednisolone (MeP), cyclosporine A (CsA) and myco-
phenolic acid (MPA), phytohemagglutinin (PHA),
PDE5 inhibitor sildenafil citrate salt, PDE4 inhibitor
rolipram, PDE3 inhibitor cilostamide, PDE2 inhibitor
erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), lipo-
polysaccharides (LPS) from Escherichia coli 0111:B4
were from Sigma-Aldrich Corp. (St. Louis, MO, USA).
EGM™ Endothelial Growth Medium & EGM™
BulletKit™ were from Lonza; fetal bovine serum
(FBS) and fetal calf serum (FCS) were from Hyclone
(Logan, UT, USA). Recombinant Human IFN-γ and
recombinant Human TNF-α were from Peprotech®
(RockyHill, NJ, USA). L-glutamine was from Gibco
Laboratories (Grand Island, NY). Granulocyte-
macrophage colony-stimulating factor (GM)-CSF,
ELISA kit for CXCL10, IL-8, and IL-6 measurement
were from R&D Systems (Minneapolis, MN, USA). For
RNA extraction, TRIzol RNA isolation reagent was
purchased by Ambion™; for reverse transcription
10 mM dNTP mix, random primers, RNaseOUT™ Ri-
bonuclease inhibitor and SuperScript® III Reverse were
purchased from Invitrogen. SYBR® Green PCR Master
Mix for qPCR was from Life Technologies™ (Applied
Biosystems®). Ficoll-Paque PLUS was from Amersham
Bioscences (Little Chalfont, UK). Trypan blue 0.5 %
was from Euroclone® (UK). Plastic ware for cell cul-
tures and disposable filtration units for growth media
preparation were purchase from Corning (Milan, Italy).
Polyclonal rabbit anti-PDE5 and monoclonal mouse
anti-β-actin were from Santa Cruz (CA, USA). All re-
agents for SDS-PAGE were from Millipore (Billerica,
MA, USA). AutoMACS® Rinsing Solution, MACS®
BSA Stock Solution, MicroBeads conjugated to mono-
clonal anti-human CD14 antibodies (isotype: mouse
IgG2a), LS MACS® columns, and MidiMACS® sepa-
rator were from Miltenyi Biotec (Bergisch Gladbach,
Germany). Fluorochrome-conjugated CD14 antibody
fo r f l ow cy tome t r i c ana lys i s (CD14-F ITC) ,
Fluorescence-activated cell sorting (FACS) Calibur and
CellQuest software for data analysis were from Becton
Dickinson (Vienna, Austria).
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Cell Cultures
Human fetal cardiomyocytes (Hfcm) and human fetal
aortic endothelial cells (Hfaec) were obtained from cardiac
tissues or aortic ascendant tracts collected after voluntary
abortion (10–12 weeks of gestation) characterized and
maintained as described elsewhere [15, 20]. Legal abor-
tions were performed in authorized hospitals, and certifi-
cates of consent were obtained. The use of human fetal
tissue for research purposes conforms with the principles
outlined in the Declaration of Helsinki and was approved
by the committee for investigation in humans of the
Azienda Ospedaliero-Universitaria Careggi, Florence, Ita-
ly (protocol no. 6783–04).
Peripheral blood mononuclear cells (PBMC) were
isolated from buffy coats obtained from healthy adult
anonymous donors in accordance with local ethical com-
mittee; approval by Azienda Policlinico Umberto I Rome
Italy, accordance with the principles outlines in the Decla-
ration of Helsinki and written consents were obtained.
Briefly, heparinized blood, collected from peripheral vein,
was centrifuged on Ficoll-Hystopaque gradient following
manufacture’s protocol. PBMC were cultured in RPMI
supplemented with 10 % FBS, 2 mmol/l L-glutamine and
antibiotics.
Monocytes were purified from total PBMC by nega-
tive selection using antibodies conjugated to magnetic
beads and cultured in RPMI supplemented with 10 %
FBS, 2 mmol/l L-glutamine and antibiotics. After isolation,
2 × 106 cells were washed twice with PBS and stained with
FITC-conjugated anti-CD14 for 30 min. After two wash-
ing steps, cells were analyzed on a flow cytometer. Cell
population purity (85–90 %) was assessed by sorting the
CD14-positive (CD14+) cells. Macrophages were obtained
from highly purified CD14+ peripheral blood monocytes
seeded onto 96-well round bottom plates in their growth
medium and treated for 5 days with (GM)-CSF (35 ng/ml).
Cell cultures in their specific growth medium were main-
tained in a fully humidified atmosphere of 95% air and 5%
CO2.
Subjects
Frozen samples from 30 subjects with diabetic car-
diomyopathy (DCM) enrolled and described in a previous
study were analyzed (Clinical Trial Registration—URL:
http://www.clinicaltrials.gov. Unique identifier:
NCT00692237) [31]. The protocol was approved by Hos-
pital Ethics Committee Policlinico Umberto I—Sapienza
University Hospital of Rome, and written informed con-
sent was obtained. This was a randomized controlled trial
with patients allocated to receive 100 mg/day sildenafil for
3 months or placebo [31]. A brief description of the proto-
col is here reported. Eligible men with type 2 diabetes were
recruited from the outpatient of Policlinico Umberto
I—Sapienza University Hospital of Rome, the inclusion
criteria were: age 35–75 years; T2DM> 1 year; glycated
hemoglobin (HbA1c) < 10 %; normal blood pressure (BP)
or treated hypertension with achievement of a target of
≤130/80 mmHg; BMI < 40. The exclusion criteria were:
use of exogenous insulin, thiazolidinediones, or
spironolactone; prior or current use of PDE5i; substance
abuse; history of cardiovascular disease, proliferative reti-
nopathy, autonomic neuropathy; symptoms or signs of
ischemic heart disease during cardiac evaluations at enroll-
ment; contraindications to sildenafil use or CMR imaging.
Concomitant medications (anti-hypertensives, statins, oral
anti-diabetics, etc.) were not changed between the months
prior to the study and 1 month after its completion. All
blood samples were collected from peripheral vein and
serum was obtained by centrifugation (3,000 rpm for
10 min at 4 °C); aliquots were stored at −80 °C until
analyzed. Analysis was performed on the active arm of
the trial (sildenafil treatment).
Two additional groups of subjects, matched for sex
and age, were analyzed for comparisons: eight subjects
affected by diabetes without signs of cardiac impairment
(DM) and eight subjects without diabetes, but with cardiac
hypertrophy (IC). Characteristics of baseline the study
population are reported in Table 1. Written informed con-
sent was collected for all subjects.
Cytokine Secretion Assay
For CXCL10 secretion assay in Hfcm and Hfaec and
for IL-8 and IL-6 assay in Hfcm, 4,000 cells/well were
seeded onto 96-well flat bottom plates and maintained for
24 h in DMEM/Ham’s F-12 medium (1:1) 10 % FBS or
Endothelial GrowthMedium (EGM™), respectively. After
overnight starvation (medium without serum and without
phenol red), cells were stimulated for 24 h with IFNγ
(1,000 U/ml) + TNFα (10 ng/ml) with or without sildenafil
(1 μM), MeP (250 ng/ml), CsA (250 ng/ml), or MPA
(26 μg/ml) in serum free medium with 0.1 % BSA. Cells
in serum-free medium containing 0.1 % BSA and vehicle
were used as control. PBMC, 200,000 cells/well, were
seeded onto 96-well round bottom plates in their growth
medium and stimulated for 48 h with 2 % PHA with or
without sildenafil (1 μM), MeP (250 ng/ml), CsA (250 ng/
ml), or MPA (26 μg/ml) in RPMI supplemented with 10 %
FBS, 2 mmol/l L-glutamine and antibiotics. Monocytes
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and macrophages, 200,000 cells/well, were seeded onto
96-well round bottom plates in their growth medium and
stimulated for 48 h with LPS (200 ng/ml) with or without
sildenafil (1 μM), MeP (250 ng/ml), CsA (250 ng/ml), or
MPA (26 μg/ml) in RPMI supplemented with 10 % FBS,
2 mmol/l L-glutamine and antibiotics.
Cells in growth medium with vehicle were used as
control. The drug concentrations were selected based on their
near-therapeutic doses, according to their pharmacokinetics
(Cmax and area under the time concentration curves, AUC).
For dose–response assays, Hfcm, after overnight star-
vation, were incubated for 24 h with IFNγ (1,000 U/
ml)+TNFα (10 ng/ml) with or without sildenafil (1 ×
10−7, 2.5 × 10−7, 5 × 10−7, 1 × 10−6, 2.5 × 10−6, 5 × 10−6,
1 × 10−5, 2,5 × 10−5 M) or MPA (8.1 × 10−7, 4.1 × 10− 6,
8.1 × 10− 6, 2.05 × 10− 5, 4.1 × 10−5, 8.1 × 10−5, 1.6 × 10−4,
3.2 × 10−4 M).
For assays with different specific inhibitors of PDE
subtypes, Hfcm were seeded, maintained, and starved in
the same conditions as described above. Cells were treated
for 24 h with IFNγ (1000 U/ml)+TNFα (10 ng/ml) with or
without sildenafil (1 μM), rolipram (10 μM), cilostamide
(1 μM), EHNA (10 μM), in serum free mediumwith 0.1 %
BSA. Cells in serum-free medium containing 0.1 % BSA
and vehicle were used as control.
Supernatants from each experimental setting were
harvested, centrifuged, and stored to −20 °C until
performing ELISA. All experiments were performed in
triplicate with at least four different cells preparations.
ELISA Assays
CXCL10, IL-8, and IL-6 levels were measured in cell
culture supernatants using commercially available kits,
according to the manufacturer’s recommendations.
The sensitivity ranged from 0.41 to 4.46 pg/ml for
CXCL10, less than 0.70 pg/ml for IL-6, from 1.5 to 7.5 pg/
ml for IL-8. The intra- and inter-assay coefficients of
variation were: 3.1 and 6.7 % for CXCL10, 4.4 and
3.7 % for IL-6, 4.6 and 8.1 % for IL-8. Quality control
pools of low, normal, and high concentrations for all pa-
rameters were included in each assay. Protein measurement
to normalize the amount of secreted cytokines was per-
formed as reported elsewhere [19]. Data were expressed as
percent of inhibition, calculated on IFNγ + TNFα-, PHA-
or LPS-induced release, taken as 100 %.
Western Blot Analysis
For protein analysis, Hfcm and Hfaec were seeded
and maintained in the same conditions as previously re-
ported [15, 20]. For PBMC and monocytes/macrophages
protein analysis, 3 × 106 cells were seeded onto 100-mm
dishes or 25-cm2 cell cultures flask, respectively, and
maintained in RPMI 1640 medium. Protein concentration
measurement was performed with Bradford Reagent.
Protein aliquots (20 μg) were processed, loaded onto
10 % SDS-PAGE, transferred on nitrocellulose mem-
branes, and incubated with primary Abs appropriately
diluted in Tween Tris-buffered saline (TTBS; for anti-









Numbers 30 16 8 8
Age (years) 61.26 ± 1.42 60.72 ± 1.33 62.65 ± 4.29 63.40 ± 4.10
BMI (kg/m2) 28.41 ± 0.89 27.60 ± 0.85 27.38 ± 1.23 25.77 ± 1.31*
Glycemia (mmol/L) 8.38 ± 1.96 8.18 ± 1.56 7.98 ± 1.65 5.08 ± 0.65*
HOMA-index 6.31 ± 0.78 7.55 ± 0.84 7.98 ± 0.52 5.08 ± 0.21*
HbAlc (%) 7.95 ± 0.23 7.33 ± 0.27 6.90 ± 0.49 5.85 ± 0.11*
Mean systolic BP
(mmHg)
136.11 ± 2.21 131.45 ± 2.85 129.14 ± 3.64 138.87 ± 3.96
Mean diastolic BP
(mmHg)
79.66 ± 1.60 78.94 ± 1.43 77.68 ± 1.40 81.75 ± 2.32
LVMi (g/m2) 124.60 ± 4.75 114.15 ± 5.96 88.62 ± 7.69† 110.68 ± 8.55
EDVi (mL/m2) 61.36 ± 1.74 60.76 ± 2.29 64.26 ± 4.11 59.16 ± 4.15
Ejection fraction
(%)
61.59 ± 1.52 59.11 ± 1.90 66.80 ± 1.81 63.12 ± 2.75
NT proBNP (pg/ml) 70.00 ± 11.88 72.23 ± 18.52 66.38 ± 4.69 81.73 ± 10.90
Values are expressed as mean ± SEM
aAll subjects (responders and no-responders)
*P < 0.05 (IC vs. DM), †P < 0.05 (DCM vs. DM)
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PDE5 and anti-β-actin 1:1,000), followed by peroxidase-
conjugated secondary IgG (1:10,000). Proteins were re-
vealed by the enhanced chemiluminescence system (ECL
plus; Millipore). Image acquisition was performed with
Image Quant Las 4000 software (GE Healthcare). Western
blot analysis was performed for three/four independent
experiments with different cell preparations.
RNAExtraction, Reverse Transcription andReal-Time
Quantitative PCR
For mRNA analysis: 35,000 Hfcm or Hfaec were
seeded in 35-mm culture dishes and maintained for 24 h in
their growthmedium; after 12-h starvation (mediumwithout
serum and without phenol red), cells were stimulated for
24 h with a combination of IFNγ (1,000 U/ml) + TNFα
(10 ng/ml) with or without sildenafil (1 μM), MeP
(250 ng/ml), CsA (250 ng/ml), or MPA (26 μg/ml) in
serum-free medium with 0.1 % BSA, cells in serum-free
medium containing 0.1 % BSA and vehicle were used as
control; 200,000 PBMC were seeded onto 96-well round
bottom plates in their growth medium and stimulated for
48 h with 2 % PHAwith or without sildenafil (1 μM), MeP
(250 ng/ml), CsA (250 ng/ml), or MPA (26 μg/ml), cells in
growth medium and vehicle were used s control. Total RNA
was extracted from cultured cells using TRIzol® RNA
Isolation Reagents (Ambion™) according to the manufac-
turer’s instructions. Single-stranded cDNAwas obtained by
reverse transcription of 1 μg of total RNA. RT-qPCRs were
performed using 7500 Real Time System (Applied
Biosystems®) with SYBR-green fluorophore; 40 ng of
cDNAwere used as template and cycling parameters were
95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C,
1 min at 60 °C, 30 s at 95 °C, 15 s at 60 °C. Fluorescence
Fig. 1 . Effect of sildenafil on cytokine-induced CXCL10 secretion in
human cells in comparison with different immunosuppressors. a In Hfcm,
a significant inhibition of IFNγ + TNFα-induced CXCL10 protein secre-
tion has been observed after 24-h incubation with sildenafil or MPA (31.8
± 7.6 and 48.3 ± 5.5% inhibition, respectively; **P < 0.01;***P < 0.001 );
no effect has been observed in presence of MeP or CsA. b Cytokine-
induced CXCL10 protein secretion by Hfaec has been significantly re-
duced by sildenafil after 24 h (*P < 0.05; 29.1 ± 6.3 % inhibition) while no
effect has been achieved in presence of the other drugs. c Sildenafil did not
affect CXCL10 release by PHA-activated PBMC after 48 h, whereasMeP,
CsA and MPA exerted a significant inhibition (MeP: 52.8 ± 12.4 %, CsA:
77.5 ± 1.2 %, MPA: 26.80 ± 7.2 % inhibition; ***P < 0.001 and
**P < 0.01). PDE5 protein expression has been detected by western blot
in all three cell types investigated (inset of a, b, and c). Results (mean ±
SE) are expressed as inhibition of CXCL10 secretion percent of IFNγ +
TNFα- or PHA-induced release, taken as 100 %. Data are obtained from
four to nine experiments using different cell preparations.
R
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intensities were analyzed using the manufacturer’s software
(7500 Software v2.05) and relative amounts were obtained
using the 2−ΔΔCt method and normalized for the ß-actin.
Data are expressed as fold increase vs. IFNγ + TNFα- or
PHA-induced expression taken as 1. Primers for CXCL10
were: forward (TTCCTGCAAGCCAATTTTGT) and re-
verse (ATGGCCTTCGATTCTGGATT); for β-actin, for-
ward (CTGAACCCCAAGGCCAAC) and reverse
(AGCCTGGATAGCAACGTACA).
Cell Viability
For cell viability assays: Hfcm and Hfaec (4,000
cells/well) were seeded in 96-well plates, maintained
in phenol red- and serum-free medium overnight and
incubated in serum-free medium containing 0.1 %
BSA with sildenafil (1 μM) for 24–48 h; cells in
serum-free medium containing 0.1 % BSA and vehi-
cle were used as control.
PBMC (150,000 cells/well) were seeded in 96-
well plates in their growth medium and stimulated with
PHA (2 %) with or without sildenafil (1 μM) for 24–
48 h. Control cells were in growth medium with vehi-
cle and PHA. In each cell type, sildenafil was added
each day. Cell viability was assessed each day by
trypan blue (0.05 % v/v solution in PBS) exclusion,
mixed in a ratio of 1:1. Cell number counting was
assayed by hemocytometer; only cells that excluded
trypan blue dye were included in the analysis. The
number of viable cells at each time point was derived
averaging at least five different fields for each well and
each experimental point was repeated in duplicate or
triplicate. Results are expressed as percent of cells at
time zero (time of seeding). Experiments were per-
formed four times with different cell preparations.
Serum CXCL10 Assay
Serum levels of CXCL10 were measured using a mag-
netic bead-based multiplex assay (Bio-Plex Pro™ Human
Cytokine, Chemokine and Growth factor assay, Bio-Rad
laboratories, Inc.) according to the manufacturer’s protocol.
A broad sensitivity range of standards (between 1.95 and
95,000 pg/ml; Bio-Rad Laboratories, Inc.) was used to en-
able the quantization of a dynamic wide range of cytokine
concentrations and provide the greatest sensitivity. Data
acquisition was performed by Bio-Plex 200 System™
(Bio-Rad Laboratories, Inc.) which uses Luminex
fluorescent-bead-based technology (Luminex) with a flow-
based dual laser detector with real-time digital signal pro-
cessing to facilitate the analysis of up to 100 different fam-
ilies of color-coded polystyrene beads and allow multiple
measurements of the sample ensuing in the effective quan-
tification of cytokines. Data analysis was performed by Bio-
Plex Manager™ 6.0 software (Bio-Rad Laboratories, Inc.).
Serum samples were run in triplicate at least twice.
Statistical Analysis
The statistical analysis was performed using 11.5
SPSS (SPSS Inc, Chicago, IL, USA). The Kolmogorov–
Smirnov test was used to test for normal distribution of the
data. Continuous data were compared using unpaired Stu-
dent’s t test or Mann–Whitney test when appropriate. Bi-
nomial data were compared using chi-square analysis and
Fisher’s exact test when appropriate. Receiver operating
characteristic (ROC) curve was constructed to identify the
best predictive CXCL10 threshold (cut-off value) capable
of discriminating between responders and non-responders
to sildenafil administration. Briefly, ROC curve gives a
graphic representation of the relationship between true-
positive fraction (sensitivity, Se) and false-positive fraction
Table 2. CXCL10 Gene Expression in Human Cardiac, Endothelial, and Immune Cells
mRNA expression (fold increase)
Sildenafil MeP CsA MPA
Hfcm 0.80 ± 0.05** 1.15 ± 0.72 1.07 ± 0.15 0.75 ± 0.14*
Hfaec 1.09 ± 0.35 1.23 ± 0.79 0.73 ± 0.1* 0.62 ± 0.07*
PBMC 1.48 ± 0.37 2.80 ± 0.65* 0.15 ± 0.06*** 1.72 ± 0.41**
mRNA expression specific for CXCL10 in Hfcm, Hfaec and PBMC is depicted after different drug treatments. In Hfcm, sildenafil and MPA significantly
inhibited CXCL10 mRNA expression (0.80 ± 0.05 **P < 0.01 and 0.75 ± 0.14 *P < 0.05 respectively)
In Hfaec, sildenafil did not exert any effect on CXCL10 gene expression; CsA andMPA significantly affected CXCL10 gene expression (0.73 ± 0.1*P < 0.05
and 0.62 ± 0.07 *P < 0.05 respectively)
In PBMC, sildenafil did notmodify CXCL10 gene expression at variance withMeP, CsA, andMPA (2.80 ± 0.65 *P < 0.05, 0.15 ± 0.06 ***P < 0.001, 1.72 ±
0.41 **P < 0.01 respectively)
Results derive from at least four different cell preparations and are expressed as fold increase vs. IFNγ + TNFα- or PHA-induced expression, taken as 1
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(1-specificity, Sp). ROC curve can be assessed by plotting
the values of 1-Sp against Se in a squared box, where the
ROC’s area under the curve (AUC) is used to measure the
performance of a diagnostic test. The AUC lies in the
interval 0.5 to 1.0, so that the greater the area, the better
the performance of the variable being examined. A P value
less than 0.05 was considered significant.
Sigmoid curves were performed using GraphPad
Prism 5 software (GraphPad Software, Inc., La Jolla, CA,
USA) and SPSS 12.0 software package (SPSS for Win-
dows 12.0, SPSS Inc.,Chicago, IL, USA). The Kolmogo-
rov–Smirnov test for normal distribution of the data, one-
way analysis of variance (ANOVA), t test were applied. A
P value less than 0.05 was considered significant and
corrected for comparison using the Dunnett’s or
Bonferroni’s post hoc test, where appropriate.
Data were expressed as the mean ± SE.
RESULTS
Effect of Sildenafil onto CXCL10 Secretion and Gene
Expression in Hfcm, Hfaec, and PBMC After
Inflammatory Activation
To verify whether PDE5 inhibition might affect Th1-
driven inflammatory response at cellular level, the effect of
sildenafil onto CXCL10 release has been evaluated in
human cardiac, endothelial, and immune cells challenged
by maximal inflammatory stimuli in comparison to MeP,
CsA, and MPA; drug concentrations have been selected on
the basis of the near therapy doses, according to their
pharmacokinetics (Cmax and area under the time-
concentration curve, AUC).
In Hfcm (Fig. 1a), sildenafil and MPA significantly
inhibited IFNγ + TNFα-induced CXCL10 protein secre-
tion (P < 0.01, P < 0.001); CsA and MeP did not exert any
significant effect. Hfcm express PDE5, as shown by west-
ern blot analysis (inset of Fig. 1a).
Sildenafil and MeP significantly inhibited IFNγ +
TNFα-induced IL-6 protein secretion (P < 0.001), differ-
ently from CsA and MPA (Fig. S1 A). Sildenafil did not
significantly affect IL-8 protein secretion similarly to
MPA, at variance with MeP and CsA (P < 0.001 and
P < 0.05, respectively, Fig. S1 B).
In Hfaec (Fig. 1b), sildenafil significantly reduced
IFNγ + TNFα-induced CXCL10 secretion—although to
a less extent as compared to Hfcm (P < 0.05)—whereas
no eff ec t has been ach ieved wi th the o the r
immunosuppressants. PDE5 protein expression has been
detected in Hfaec (inset of Fig. 1b).
In PBMC, sildenafil did not change PHA-
induced CXCL10 release, at variance with the other
immunosuppressants (P < 0.01 and P < 0.001, Fig. 1c).
PBMC express PDE5 protein (inset of Fig. 1c).
Fig. 2. Sildenafil-induced dose-dependent inhibition of CXCL10 se-
cretion and IC50 calculation in human cardiomyocytes. a Incubation
with increasing doses of sildenafil (1 × 10−7, 2.5 × 10−7, 5 × 10−7, 1 ×
10−6, 2.5 × 10−6, 5 × 10−6, 1 × 10−5, 2.5 × 10−5 M) significantly and
dose-dependently reduced CXCL10 protein release, starting from
5 × 10−7 M, by Hfcm stimulated with IFNγ (1,000 U/ml)+TNFα
(10 ng/ml). The IC50 was 2.6 × 10
−7 M. b MPA (8.1 × 10−7, 4.1 ×
10−6, 8.1 × 10−6, 2.05 × 10−5, 4.1 × 10−5, 8.1 × 10−5, 1.6 × 10−4, 3.2 ×
10−4 M), used for comparison, has been confirmed to induce a dose-
dependent inhibition of cytokine-induced CXCL10 release by Hfcm,
starting from 4.1 × 10−6, with an IC50 = 4.6 × 10
−6 M, similar to
sildenafil, although one log higher. Data are derived from six
separate experiments using distinct cell preparations. CXCL10
secretion is expressed as percent of IFNγ + TNFα-induced
secretion (mean ± SE). *P < 0.05; **P < 0.01; ***P < 0.001.
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In monocytes sildenafil, CsA and MPA did not exert
any significant effect on LPS-induced CXCL10 release,
while MeP induced a significant inhibition (P < 0.05,
Fig. S2a). None of the tested drugs affected LPS-induced
CXCL10 secretion by macrophages (Fig. S2b).
Monocytes purity was assessed by FACS analysis
before and after CD14 magnetic beads separation and
was around 10 and 90 % of total cell population, respec-
tively (Fig. S2c, left and right representative panels).
mRNA expression specific for CXCL10 after the
different drug treatments has been investigated in each
tested cell type and reported in Table 2 and related legend.
In particular, sildenafil and MPA significantly inhibited
CXCL10 mRNA expression in Hfcm (P < 0.01 and
P < 0.05, respectively); no significant effect has been ob-
served in Hfaec and in PBMC after sildenafil.
IC50 Determination in Hfcm
Since sildenafil and MPA exerted a similar inhibitory
effect on CXCL10 release in Hfcm, we compared drug
potency in vitro in these cells. As we performed dose–
response curves in Hfcm induced by inflammatory
Fig. 3. Effect of different PDE subtype blockage on cytokine-induced
CXCL10 release by human cardiomyocytes. The specific blockage for
24 h of PDE3 activity with cilostamide (1 μM) almost blunted IFNγ +
TNFα-induced CXCL10 release by human cardiomyocytes (82.4 ± 9.9 %
inhibition, ***P < 0.001, #P < 0.05 vs. sildenafil treatment); PDE5 and
PDE4 inhibition by sildenafil (1 μM) and rolipram (10 μM), respectively,
significantly inhibited CXCL10 secretion (28.6 ± 10.7 and 25.5 ± 9.8 %
inhibition, respectively, **P < 0.01); PDE2 blockage with EHNA (10μM)
had no significant effect (−24.0 ± 22.6 % inhibition). Results (mean ± SE)
are expressed as inhibition of CXCL10 secretion, percent of IFNγ +
TNFα-induced release, taken as 100 %. Data are obtained from
experiments with four different cell preparations.
Fig. 4. Effect of sildenafil on human cardiac, endothelial and immune cell
viability. a Hfcm cell viability did not change after 24 or 48 h treatment
with sildenafil (1 μM, square) vs. control cells (rhombus). b Hfaec viabil-
ity was unvaried after 24- or 48-h treatment with sildenafil (1 μM, square)
vs. control cells (rhombus). c. PBMC viability after 24–48 h did not
change with sildenafil (1 μM, square) vs. control cells (rhombus). Results
derived from at least four different cell preparation for each cell type and
are expressed as percent of control cells (taken as 100 %) at time 0.
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cytokines and incubated with scalar concentration of sil-
denafil or MPA, for comparison, we found that sildenafil
decreased, in a dose-dependent manner, cytokine-induced
CXCL10 secretion, significantly from 5 × 10−7 M
(P < 0.05, P < 0.01 or P < 0.001 vs. IFNγ + TNFα-
induced secretion; Fig. 2a). MPA has been confirmed to
inhibit CXCL10 secretion dose-dependently (Fig. 2b,
P < 0.01, P < 0.001 vs. IFNγ + TNFα-induced secretion),
as previously shown [34]. The calculated IC50 was 2.6 ×
10−7 M for sildenafil and 4.6 × 10−6 M for MPA, in line
with our previous results [34].
Effect of Sildenafil onto CXCL10 Protein Secretion in
ComparisonwithOther PDE Subtype Blockage inHfcm
As we found that human cardiomyocytes were signif-
icantly targeted by sildenafil in terms of CXCL10 inhibi-
tion at protein and gene level, we compared cytokine-
induced CXCL10 release by Hfcm after PDE subtype 5,
4, 3, and 2 specific blockage (Fig. 3). CXCL10 significant-
ly decreased after PDE5 and PDE4 inhibition by sildenafil
and rolipram, respectively (P < 0.01). PDE3 inhibition
with cilostamide almost abrogated IFNγ + TNFα-induced
CXCL10 secretion (P < 0.001), while PDE2 blockage with
EHNA exerted no effect.
Effect of Sildenafil on Hfcm, Hfaec, and PBMC
Viability
Sildenafil did not affect Hfcm, Hfaec and PBMC
viability after 24–48 h as compared with control cells,
Fig. 4a, b, c.
Fig. 5 . Effect of sildenafil on circulating CXCL10 level in diabetic cardio-
myopathy. aReceiver operating characteristic (ROC) analysis evidenced that
serum CXCL10 = 930 pg/ml (cut-off value, open circle) had good capability
to discriminate subjects who did or did not respond to sildenafil administra-
tion, in terms of circulating chemokine decrease. The area under the ROC
curve (AUC) resulted 0.80 (95 % confidence interval = 0.584–0.996,
P< 0.01) with a sensitivity of 0.78 and a specificity of 0.69. b Subjects have
been categorized as drug responders (r) and non-responders (nr) to sildenafil
treatment. Positive or negative variations in circulating CXCL10 have been
observed after sildenafil intake vs. basal level (504.84 ± 182.6 pg/ml,
−323.93 ± 82 pg/ml). Data are expressed as serum CXCL10 change, in
picogram per milliliter vs. basal level (mean ± SE); (**P < 0.01,
***P < 0.001, vs. basal level). c r and nr subgroups showed significant
difference in CXCL10 basal level (1514.92 ± 221.22 pg/ml vs. 923.45 ±
76.71 pg/ml, respectively ##P < 0.01); CXCL10 level in diabetes (DM,
1719.46 ± 151.4 pg/ml) was similar to basal level in r subgroup and higher
than basal level in nr subgroup (##P < 0.01). Subjects with non-diabetic
cardiomyopathy (IC) displayed circulating CXCL10 (1186.39 ± 162.38 pg/
ml) lower than DM and r (°P < 0.05). Data are expressed as basal serum
CXCL10 level, in picogram per milliliter (mean ± SE).
b
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Effect of Sildenafil onto CXCL10 Serum Level in
Diabetic Cardiomyopathy
To verify whether PDE5 inhibition might affect
in vivo Th1-associated conditions, we measured CXCL10
level in blood of subjects with diabetic cardiomyopathy
before and after sildenafil intake. Receiver operating char-
acteristic (ROC) analysis (Fig. 5a) showed that circulating
CXCL10 = 930 pg/ml is the cut-off value retaining a good
ability to discriminate between patients with positive or
null/negative response to sildenafil (Fig. 5b): this means
that drug intake induced a significant decrease of chemo-
kine level only in subjects with circulating CXCL10 over
930 pg/ml (positive change, P < 0.001); subjects with
CXCL10 below cut-off value showed no change or an
increase (null/negative change, P < 0.01) in serum chemo-
kine level; subjects were then defined as (r) responders and
non-responders (nr) to sildenafil.
CXCL10 level was significantly different in r and nr
subgroups (P < 0.01, Fig. 5c);in particular, r subgroup
showed CXCL10 serum level similar to subjects affected
by diabetes without sings of cardiac disease (DM), but
significantly different from subjects with non-diabetic car-
diomyopathy (IC, P < 0.05 vs. DM and r; Fig. 5c).
DISCUSSION
The main finding of this study is that sildenafil in
human cardiomyocytes inhibited protein and gene expres-
sion of IFNγ + TNFα-induced chemokine CXCL10 (IC50
2.6 × 10−7 M), which is a critical trigger of early Th1
immune/inflammatory response during cardiac diseases
[12–17]. Sildenafil also significantly reduced inflammato-
ry cytokine-induced IL-6 secretion by Hfcm. Furthermore,
sildenafil decreased CXCL10 blood level higher than
930 pg/ml (cut-off value) in diabetic subjects at cardiomy-
opathy onset.
Cardiovascular homeostasis is tightly linked to the
immune/inflammatory status. Th1-type inflammatory
dominance is considered the common link in several co-
morbid conditions, such as diabetes, atherosclerosis, and
heart dysfunction [1, 2]. A number of Th1-related inflam-
matory molecules, produced by different tissues and cells,
have been shown to widely participate to disease initiation
and progression, as well [12–17]. In this scenario, heart-
related studies began to focus on the complex communi-
cations between cardiomyocytes and other cells—i.e., en-
dothelial and inflammatory cells recruited to and residing
within the heart. Th1-type cytokines and chemokines have
been shown to be highly active mediators in cell-to-cell
interactions through endocrine, paracrine or autocrine path-
ways, triggering immune/inflammatory response [6, 9, 37]
at disease onset. In particular, previous human in vivo and
in vitro studies reported that CXCL10, released by cardiac,
endothelial and immune cells challenged by inflammatory
conditions could be eligible as reliable marker and thera-
peutic target at early stages of heart disease, when Th1-type
dominance prevails [12, 13, 15, 20, 38].
Recently, the use of oral PDE5i to treat different
cardiac diseases has been sustained and encouraged by
several animal and clinical evidences [23, 31, 37, 39–44].
In particular, sildenafil has been evolving from an anti-
angina drug to a treatment for ED and, afterward, it has
been approved for primary pulmonary hypertension [38,
45–47]. PDE5i beneficial effects seem undoubtedly linked
to sildenafil-induced vascular tone regulation: through
PDE5 selective inhibition, the release of endogenous
cardioprotectivemolecules (i.e., adenosine and bradykinin)
from vascular bed would be promoted, cause/effect rela-
tionships in heart tissue accomplished and cardiac cell
protection indirectly achieved [48].
In a rat model of pulmonary hypertension, novel
mechanisms for sildenafil protection have been shown to
relay on preservation of lung morphology, attenuation of
inflammatory paths with reduction of several cytokine
release, finally ending in a decrease of inflammatory cell
infiltration [49].
We provide the first evidence that sildenafil in human
cardiomyocytes could counteract CXCL10 protein release
with a potency similar to MPA—although with an IC50 of
one log lower—and chemokine-specific mRNA expres-
sion, as well.
We have previously reported that in Hfcm CXCL10
secretion is mediated by the nuclear transcription factor-kB
(NF-kB) and that drug-induced reduction of CXCL10 re-
lease by human cardiomyocytes is associated to a block of
NF-kB nuclear translocation [20, 38].
We could speculate that in Hfcm sildenafil is able to
repress NF-kB activity acting at transcription level via
cGMP stabilization, as shown in previous studies [50,
51]; in line with this hypothesis, cGMP level increased in
Hfcm after sildenafil, similarly to Hfaec (not shown); our
ongoing study aims to clarify those underlying biomolec-
ular mechanism(s).
Conversely, in Hfaec stimulated by proinflammatory
cytokines, sildenafil did not affect CXCL10 mRNA ex-
pression while chemokine protein release was reduced,
albeit to significantly less extent than in Hfcm. In TNFα-
stimulated human endothelial cells promoter targeting and
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transcriptional activation of CXCL10 has been shown to
depend on NF-kB activation as well [52]. Changes in
transcription not always reflect changes in protein expres-
sion [53] and differences in protein/mRNA expressionmay
result from gene transcription, specific mRNA stability or
translation [54–62]. A deregulation at post-trascriptional
level, concerning, i.e., mRNA processing/maturation or
stability could result in reduction of translated CXCL10
protein in Hfaec treated with sildenafil [63].
In PHA-activated PBMC sildenafil affected CXCL10
expression neither at protein nor at gene level. Similarly,
sildenafil did not exert any significant effect onto CXCL10
released by activated monocytes and macrophages. The
lack of significant effects onto immune cells would suggest
the exclusion of possible specific modulating effects on
immune system by sildenafil.
In this research, we have screened CXCL10 mRNA
expression in Hfcm, Hfaec, and PBMC 24 h after stimula-
tion, at time when the maximal induction of chemokine
protein release occurs in all cell types [15]; however, the
discrepancy found in CXCL10 protein/mRNA expression
after sildenafil in cardiac, endothelial and immune cells can-
not exclude some experimental conditions, since incubation/
harvest time could be differentially optimal for mRNA de-
tection depending on different cell types. Our future gene
studies will include fine-tuned time-course assays.
Concerning in vivo data, we show that in dia-
betic cardiomyopathy serum CXCL10 positive or
negative variation after sildenafil intake categorized
subjects as drug responders vs. non-responders; in
fact, as revealed by ROC analysis, CXCL10 serum
level equal or higher than cut-off value (930 pg/ml)
is significantly predictive of response to sildenafil.
This means that subjects (half number) showing basal
circulating CXCL10 level higher than the cut-off
value responded to sildenafil treatment with a signif-
icant decrease of the chemokine in blood (positive
variation); hence, those subjects have been defined as
“responders”. No decrease in serum chemokine level
(null/negative variation) after drug intake has been
found in subjects with basal circulating CXCL10
levels lower than 930 pg/ml, and, therefore, named
“non-responders”.
As we evaluated sex- and age-matched subjects
affected by diabetes or cardiomyopathy at the same
disease stage as patients with comorbidity, we found
that cardiomyopathy per se does not display high
systemic CXCL10 with sera values similar to non
responders (and healthy subjects, not shown) at var-
iance with diabetes. This latter result could be due to
the wide involvement of this chemokine in diabetes-
associated vascular bed alterations [37, 64], where
CXCL10, among other Th1-type biomediators, is de-
scribed to be increased (devaraj et al. 2009 cytokine)
and responsible for triggering vascular alteration and
damage [14, 64].
We could speculate that in some subjects, re-
gardless DM or DM-induced cardiomyopathy, the
higher CXCL10 level in blood likely derives from
different cell and tissue types and could mirror a
wider activation and amplification of the Th1-type
response, during which sildenafil seems to be effec-
tive while it is neutral when CXCL10 is below the
cut-off level, as from our ROC analysis data.
Interestingly, a recent meta-analysis reports that sil-
denafil causes significant improvements only in subjects
with heart failure (HF) and reduced ejection fraction [65]
without any beneficial effect in HF subjects with preserved
ejection fraction [66, 67]. So far, it is likely that PDE5
inhibition would be capable to oppose “destabilized” ho-
meostatic conditions with an anti-inflammatory action po-
tentially associated with clinical favorable outcome.
This topic is presently under debate along with the
presence of PDE5 expression in heart [66].
A recent study by Degen et al. [68] was unable
to detect PDE5 protein expression in tissues from
healthy and failing heart of humans and addressed
the lack of therapeutic effect of sildenafil in
HF—shown by RELAX trial or similar studies [67,
69]—on the basis of PDE5 low level/absence. Nev-
ertheless, PDE5 upregulation has been detected in
inflammation-related processes, i.e., oxidative stress
and pressure overload hypertrophy [70–74], and
would explain the favorable effects on cardiac func-
tion achieved by PDE5 inhibition. So far, the current
hypothesis is that PDE5 expression is undetectable in
normal myocardium, upregulated during hypertrophy
and downregulated in end-stage HF [68]. In this
light, human heart tissue collection obtained at time
of heart transplantation in end-stage HF, when PDE5
expression is downregulated below detection limits,
would justify the absence of specific protein signal as
shown by Degen et al. [68].
In cell lysates from Hfcm, we have detected
PDE5-positive-specific signal, similarly to Hfaec and
all immune cell tested by western blot analysis per-
formed with the same antibody reported by Degen
et al. [68]. It is possible that specific signal detection
could be technically easier using cell lysates from
virtually pure culture of human cardiomyocytes,
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which require sample processing different from tissue
lysates.
CONCLUSIONS
The potential advantage of PDE5i use in cardio-
vascular diseases has been assumed to be based on
counteracting some pathophysiologic perturbations,
i.e., attenuation of adrenergic stimulation, reduction
of ventricular–vascular stiffening and maladaptive
chamber remodeling, together with improvement of
endothelial function, hemodynamics and enhancement
of renal responsiveness [75, 76].
In line with previous data showing that sildenafil is
associated with cardioprotection and reduction of multiple
circulating inflammatory cytokine levels in Th1-driven
conditions [31, 49], herein, we reported that sildenafil
reduced high circulating CXCL10, likely deriving from
multiple cell types activated during Th1-driven
inflammation.
Our results obtained in human cardiomyocytes and
endothelial cells suggest that sildenafil can counteract Th1-
driven processes by targeting CXCL10 at local cellular
level.
This observation seems particularly relevant since
CXCL10, engaged in cardiac disease onset, is not linked
to generic inflammatory status but critically initiates the
response to Th1-driven inflammatory challenge and trig-
gers a self-detrimental loop [12–16]. Remarkably, the spe-
cific inhibition of PDE3, that is well recognized to retain
cardioprotective effects [29], almost blunted CXCL10 se-
cretion by Hfcm as well. However, it is unlikely that
sildenafil effect may be limited to CXCL10; indeed, we
might hypothesize that the inhibition of IL-6 release by
human cardiac cells might contribute as well to sildenafil-
induced cardioprotective effects. IL-6, as a cardiomyocyte-
derived cytokine, has been shown to start positive feedback
circuits and promote cytokine amplification, thereby con-
tributing to chronic inflammatory state establishment [77].
Conversely, our results in human cardiomyocytes on mod-
ulation of IL-8 did not evidence significant effects after
sildenafil. However, further fine-tuned investigations on
possible sildenafil effects onto those and other tissue/
systemic cytokines are necessary, also considering that
temporal regulation of those biomediators might result in
protective or pathogenic effects, as recently reported for IL-
6 [78].
Finally, our in vitro and in vivo study present some
limitations, i.e., the limited number of biomediators
analyzed, or the lack of group of subjects with diabetes
mellitus or cardiomyopathy alone treated with sildenafil. In
conclusion, albeit we cannot correlate the results obtained in
cells and in patients, our data showed that sildenafil targets
CXCL10 in Th1-type-dominant conditions and contribute to
confirm the anti-inflammatory properties of this drug.
Further in vivo investigations, including a larger
number of cytokine types and patients, different
stages of cardiomyopathy, longer treatment with sil-
denafil and follow-up evaluation are mandatory as
well as additional in vitro studies on biomolecular
mechanism(s) in order to elucidate intracellular tar-
get(s) in cell target-based PDE5i pharmacokinetic
studies. In light of those preliminary evidences, we
speculate that sildenafil could be a new therapeutic
option to control cardiomyopathy onset/progression in
diabetic subjects while CXCL10 could represent a
novel tool to identify patients to treat since early
stages.
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